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Inhalation of particles, gases, and vapors from
environmental pollution produces numerous
localized and general responses by the lungs.
These responses can involve distinct processes
such as neural reflex responses and chemical
interactions with lung structures, and may
initiate alterations in the distribution of venti-
lation and perfusion. In this article we report
investigations performed in humans that have
enabled the identiﬁcation of speciﬁc processes
in response to inhaled materials. We offer
insights that are generalizable to environmen-
tal inhaled pollutants and potential means of
studying them in humans.
We cover three specific areas. The first
describes the impact of denervation of the
lungs and airway inﬂammation on the acute
defense mechanism of the lungs to inhaled
“irritants,” namely cough and bronchocon-
striction responses. Here we discuss physio-
logic studies of heart–lung transplantation
(HLT) in humans. The second area illustrates
differential uptake of inhaled particles into
separate regions of the lungs with emphasis on
the importance of physiochemical properties
of the inhaled materials in determining their
site of interaction and the manner of inhala-
tion. Third, we assess the effect of inhaled
nitric oxide (NO) on the pulmonary vascula-
ture and gas exchange. The inhaled NO draws
out the potential of inhaled pollutants to
inﬂuence gas exchange, especially in patients
with established lung disease, such as chronic
obstructive pulmonary disease (COPD).
Importance of Lung Reﬂexes and
the Interaction of Nerves and
Inﬂammation in Determining
Airway Responses: Lessons from
Heart–Lung Transplantation
HLT was introduced in 1981 (1) for
treatment of pulmonary hypertension. The
operation involves an airway anastamosis at
the lower end of the trachea. All nerves to
the lungs below this level are lost. Studies on
reinnervation (2) have shown loss of the air-
way afferent nerves. Only postganglionic
nerves are retained and these were found not
to contain substance P. The central airways
in humans are richly supplied by myelinated
and nonmyelinated afferent nerves (3).
Myelinated nerves extend to the spaces
between the epithelial cells of the airway
mucosa (4,5). Myelinated nerves and non-
myelinated afferent nerves are both mechani-
cal receptors, responsive to pressure, and
chemoreceptors, responsive to irritants (3)
and to changes in osmolarity and chloride
concentration of airway surface liquid (6).
The study of cough in HLT patients used
aqueous, low-chloride concentrations, dis-
tilled water, nebulized by an ultrasonic
device. Unlike normal individuals, these
patients had lost the cough reflex elicited
from the lungs (7). However, if distilled
water was added to the larynx directly, dur-
ing bronchoscopy, cough was still elicited.
The results of this study, taken with evidence
of afferent nerve loss after HLT, clearly indi-
cated the role of the airway’s rapidly adapting
afferent receptors in initiating cough in
humans, as distinct from the role of laryngeal
receptors.
Despite this evidence of denervation,
patients after HLT still showed evidence of
airway bronchial hyperresponsiveness.
However, enhanced nonspecific bronchial
hyperresponsiveness with methacholine, hist-
amine, and ultrasonically nebulized distilled
water is seen in patients only at times of
acute lung rejection (8). It proved possible to
demonstrate a relationship between the
presence and degree of airway mucosal
lymphocytic infiltration and the severity of
nonspecific bronchial hyperresponsiveness.
Detailed histologic studies of transbronchial
biopsy during acute rejection and after treat-
ment showed infiltrates of both airway and
mucosa consisting predominantly of lym-
phocytes, neutrophils, and eosinophils.
Steroids reduced these infiltrates within 3
weeks. Another measure of bronchial hyper-
responsiveness is diurnal variation of peak
flow (9). HLT patients at times of acute
rejection show marked diurnal variation in
peak ﬂow (10). The enhanced diurnal varia-
tion is lost with steroid treatment associated
with the clearing of airway mucosal lympho-
cytic infiltration. The bronchoconstrictor
response to inhaled irritants such as hista-
mine, methacholine, and distilled water does
not require innervation of the lungs. Instead
it requires specific cellular infiltration of the
airway mucosa. This difference has special
importance in highlighting the susceptibility
of asthmatic patients to inhaled environmen-
tal pollutants, which depends on an equiva-
lent airway inﬂammation. 
Inhaled capsaicin, which causes bron-
choconstriction in asthmatics but not in
normal volunteers, offers further insights
into airway responses. In HLT patients,
even when they are methacholine hyperre-
sponsive, capsaicin fails to induce bron-
choconstriction (11). This suggests that
capsaicin represents a distinctive challenge to
the airway in that it requires both an intact
airway innervation and the presence of an
airway-specific cellular infiltrate to cause
bronchoconstriction. These observations
could again be of special relevance to the
behavior of asthmatic patients to environ-
mental irritants such as sulphur dioxide and
even nitrogen dioxide, which probably
require the presence of capsaicin-sensitive
nerves as well as airway inflammation (12).
Therefore, the components of the acute
responses of the lung to inhaled environ-
mental irritants clearly are initiated through
both neural and inflammatory processes.
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Separate chemical interactions with the
airway may elicit pure neural reflex cough-
ing, whereas other types of reaction require
the presence of inflammation in the airway
mucosa to initiate bronchoconstriction.
Those reactions, which act through the cap-
saicin nerves, require the enhancement of
airway inflammation to induce broncho-
constriction (Figures 1, 2).
The Impact of Inhalation
Pattern and Chemistry on 
the Distribution of Inhaled
Pollutant Effects: Lessons 
from Tobacco Smoking
In humans one of the most extensively studied
environmental pollutants is tobacco smoke
from cigarettes. In the developed nations
more than 25% of the adult population
smokes (13). This form of self-injury produces
both pulmonary and systemic disease.
Tobacco smoke provides an example of how a
complex aerosol can be absorbed and con-
tribute to disease at sites distal from the lungs.
The pattern of smoking varies enormously
among individuals. There are two extremes,
either “deep inhalation” or “mouth” smoking.
Some individuals retain smoke in the mouth
and upper airway; others inhale deeply. All still
access smoke to their lungs (14). Those who
inhale less are at a much higher risk of develop-
ing lung cancer than those who take deep
inhalations of smoke (15). This phenomenon
was attributed to the fact that the concentra-
tion of smoke in the upper airways, trachea,
and major bronchi was higher in those who
did not inhale fully. Depositing the smoke in
these airways creates a higher concentration of
smoke particles and little access to the phago-
cyte cells such as the alveolar macrophage and
thus contributes to the development of cancer.
Conversely, in the so-called inhalers there was
a much higher mortality rate from coronary
artery disease (15). Here, higher alveolar
uptake of smoke constituents exposes the body
to the systemic effects of the tobacco smoke.
The coronary artery risk diminishes within a
year of quitting smoking, which has been
attributed to the reversible effects when the
speciﬁc constituent of the smoke is withdrawn.
Continued exposure is necessary to maintain
coronary heart disease risk. 
Besides the inhalation pattern, the chem-
istry of the smoke also helps determine the site
of action. The differential uptake of tobacco
smoke depends on the physiochemical proper-
ties of its constituents and on how these char-
acteristics influence lung retention. Table 1
shows the mouth and pulmonary retention of
different constituents of smoke according to
their water solubility. The water-soluble
acetaldehydes are retained in the aqueous lin-
ings of the mouth; the water-insoluble toluene
is retained in those regions of the lungs where
there is surfactant, e.g., the alveolar epithe-
lium. The lipophilic nature of the surfactant-
coated epithelial surface probably contributes
to the retention of the lipophilic constituents
of complex aerosols such as tobacco smoke.
The particulates—the tar—are retained prin-
cipally on deep inhalation because of the
lipophilic nature of their hydrocarbon con-
stituents. One constituent of tobacco smoke,
nicotine, coexists in the volatile and particu-
late fractions of the smoke. It is taken up by
both the airways and alveoli with almost equal
facility due to its unique physiochemical prop-
erties allowing access to both the aqueous sur-
face liquid of the airways and the lipophilic
alveolar surfaces.
Another constituent of tobacco smoke
selectively taken up by the alveolar pulmonary
capillaries is NO. Again, this is a result of its
unique chemical properties. Our original
studies showed that NO-like carbon monox-
ide (CO) was not taken up by the airways.
Figure 2. Levels of airway responses.
Figure 1. Response to inhaled capsaicin was measured
by the greatest percent change in FEV1 achieved for HLT
patients, normal subjects, and asthmatic patients. Eight
HLT patients showed bronchodilation, seven asthmatic
patients showed bronchoconstriction, and no normal
subject responded.
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Table 1. Differential retention of tobacco smoke con-
stituents in the mouth and in the lungs.
Retention of cigarette smoke constituents
Water Boiling
soluble point (°C) % Lung % Mouth
Acetaldehyde Yes 21 99 60
Isoprene No 34 99 20
Acetone Yes 56 86 56
Acetonitrile No 85 91 74
Toluene No 111 93 29
Particles No _ 96 16
Carbon No _ 54 3
monoxide
Data from Higenbottam (32).Effects of inhaled agents on pulmonary circulation
However, on contact with the alveolar
capillaries it was taken up 4.5 times faster than
carbon monoxide (16). The solubility of NO
in water is greater than oxygen (O2) or CO
but it is still very low (Table 2). By contrast it
has 400,000 times the afﬁnity that oxygen has
for hemoglobin (17). This high value for
afﬁnity reﬂects the ratio of the published rate
constants for the forward and reverse reactions
for NO and O2 with hemoglobin, as NO
reacts with hemoglobin in the red corpuscles
to form methemoglobin and nitrate (18). The
abundant presence of methemoglobin reduc-
tase restores the methemoglobin to hemoglo-
bin for further O2 carriage.
Inhaled Pollutants That Alter
Gas Exchange of the Lungs
and Systemic Uptake: Lessons
from Inhaled Nitric Oxide
In 1987 we undertook the first studies of
inhaled NO in patients with primary pul-
monary hypertension (19). It appeared that 40
parts per million (ppm) NO was able to cause
selective pulmonary vasodilation with few or
no effects on systemic vascular resistance
(Figure 3). From these observations many
studies were undertaken which culminated in
the use of inhaled NO in the treatment of per-
sistent pulmonary hypertension of the neonate
(20). As a result, inhaled NO was registered as
a treatment of persistent pulmonary hypo-
tension of the neonate in December 1999.
Inhaled Nitric Oxide in Chronic
Obstructive Pulmonary Disease
It was hoped that inhaled NO could be used
to treat a range of lung diseases. One such
common disease was COPD, a disease state
characterized by airﬂow limitation that is not
fully reversible. The airﬂow limitation is usu-
ally both progressive and associated with an
abnormal inflammatory response to noxious
particles and gases (21). We found that in
patients with COPD and with forced expira-
tory volume in 1 sec (FEV1) values below 1.5
L, inhaled NO induced a fall in arterial oxygen
partial pressure (PaO2) (22). We were able to
demonstrate, using the multiple inert gas elim-
ination technique (MIGET), that inhaled NO
negatively affected the ventilation/perfusion
(V/Q) matching (Figure 4). These data suggest
that the distribution of NO to poorly venti-
lated alveoli reversed hypoxic vasoconstriction.
We suspect that variation in local NO produc-
tion by the pulmonary endothelium con-
tributes to local perfusion. It has been shown
that endothelial NO release falls with acute
hypoxia (23), and this could also contribute to
the regional hypoxic vasoconstriction and
matching between ventilation and perfusion.
The opportunity to test the idea has been
made possible with the introduction of the
“spiked” inhaled NO delivery system (24).
This device was designed to provide a safe and
practical way of delivering inhaled NO to the
ambulatory patient. The spike device releases
a bolus of NO at the onset of inspiration trig-
gered by each breath (Figure 5). This not only
reduces the amount of NO given in each
breath, but also targets NO to the alveolar
region of the most rapidly ventilated parts of
the lungs. When COPD patients inhale
spiked NO, the mismatch of V/Q is very
much reduced and PaO2 does not fall as it
does when NO is mixed in the whole inspired
breath (25). We have demonstrated that
although spiked inhaled NO prevents a drop
in oxygenation, the reduction in pulmonary
artery pressure is as effective as when NO is
delivered in the whole inspired breath (26).
The lessons to learn from these observations
are that gases diffuse to all regions of the lungs
even in the presence of extensive COPD and
emphysema. If vasodilatation occurs in poorly
ventilated regions, PaO2 can fall as a conse-
quence of a worsening of V/Q matching. 
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Table 2. Nitric oxide, oxygen, and carbon monoxide sol-
ubility at 35°C in water.
Compound Solubility coefﬁcient (mL/mL)
NO 0.042
CO 0.021
O2 0.028
Data from Wilhelm et al. (33).
Figure 3. Comparison of effects on (A) pulmonary (PVR) and (B) systemic (SVR) vascular resistance of an infusion of
PGI2 (0.5 mg in 250 mL) at rates of 4, 8, and 12 mL/hr and inhalation of NO (40 ppm in air) with baseline (BL) values in
eight patients with pulmonary hypertension. Means ± SEM are shown. * p < 0.05; ** p < 0.01.
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Figure 4. Effect of inhaled nitric oxide on distribution of
ventilation–perfusion ratios in a subject with severe
chronic obstructive pulmonary disease (35).
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This ﬁnding offers an explanation for the
fall in O2 levels even in the absence of bron-
choconstriction or alveolar edema. These
observations illustrate how inhaled vasoactive
air pollutants can worsen gas exchange in
patients with existing lung diseases.
Systemic Uptake of Nitric Oxide
Although NO causes selective pulmonary
vasodilation as a result of most of the gas
reacting with hemoglobin to form methemo-
globin, and nitrate, there is some evidence of a
systemic effect associated with the use of
inhaled nitric oxide. For example, myocardial
function can be reduced (27). We have argued
that nitrite can act as a circulating NO donor
(28). When NO is exposed to aqueous solu-
tion it dissolves and is oxidized to nitrite. In
vivo, NO is found in nanomolar concentra-
tions whereas nitrite and nitrate are present in
micromolar concentrations. Nitrate is largely
unreactive and is the principal excretion prod-
uct of nitric oxide (29). Nitrite, however, can
release NO by disproportionation of its conju-
gated acid, nitrous acid, a process dependent
on both temperature and pH: 
3HNO2 ⇔ 2NO + NO3
– + H+ + H2O 
We have shown that nitrite causes relax-
ation of the pulmonary artery partly by release
of NO, which may be detected in the exhaled
air (30). The circulating level of plasma nitrite
is between 0.1 and 15 µM (31). Increase in cir-
culating nitrite, which can release NO, causes
systemic vasodilation (32). We can therefore
see how a small but signiﬁcant systemic effect
can be produced by an inhaled gas such as NO
as a consequence of its reaction with blood.
Equivalent systemic uptake of inhaled pollu-
tant might contribute to systemic disease.
These observations in humans further empha-
size the need for translating the concentration
of an inhaled material to an estimated dose on
the epithelial surface of the lungs. The need to
achieve this dose has importance not only for
toxicology but also for the rapidly expanding
ﬁeld of inhaled drug therapy.
Conclusion
These three areas of human physiopathology
introduce several important concepts. Sensory
innervation of the lungs is necessary for cough-
ing. Conversely, bronchial hyperresponsiveness
to nonspeciﬁc challenges—e.g., methacholine,
histamine, and distilled water—depends on
speciﬁc types of cellular inﬁltrates of the airway
mucosa. Capsaicin, however, requires the air-
ways to be innervated to cause bronchocon-
striction. Uptake of constituents of tobacco
smoke and their capacity to cause disease
depend on their chemical properties and their
distribution when inhaled into the lungs.
Nitric oxide, through its unique capacity to
combine with hemoglobin when inhaled, acts
as a selective vasodilator. However, its capacity
to override hypoxic vasoconstriction in
patients with COPD worsens the matching
between distribution of ventilation and perfu-
sion and improved gas-impaired gas exchanges.
Chemical pollutants, such as nitric oxide, may
exert a physiologic effect. Indeed, mining acci-
dents in the early part of the 20th century
recorded the hemodynamic effects of inhala-
tion of the gas. We must be aware of the
potential vascular effects and of the possibilities
of alterations in gas exchange, particularly
when individuals with disease are involved.
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